Table 1.
Clinical information and the CGP results of simulated cases
| Case 1 | Case 2 | |
|---|---|---|
| Gender | Male | Female |
| Age | 50s | 40s |
| Tumor type | Colon cancer | Breast cancer (ER+, PgR+, HER2 1+) |
| Previous chemotherapies | ||
| 1st line | FOLFOX + bevacizumab | Anastrozol |
| 2nd line | FOLFIRI + cetuximab | Fulvestrant + palbociclib |
| 3rd line | Investigational drug | Paclitaxel + bevacizumab |
| 4th line | Regorafeinib | Eriblin |
| 5th line | – | Capecitabin |
| 6th line | – | Doxorubicin + cyclophosphamide |
| Family history of cancer | Mother: breast cancer (40s) | N/A |
| Sister: breast cancer (50s) | ||
| Medical history | Hypertension | N/A |
| Type of GCP test | OncoGuide™ NCC oncopanel | FoundationOne® CDx |
| Detected SNVs and CNVs | Somatic variants | |
| BRAF V600E | PIK3CA H1047R | |
| ATM R35* | ERBB2 S310Y | |
| NF1 Y1521* | CCND1 amplification | |
| TP53 R273H | ||
| APC c.1312+1G>A | ||
| ARAF R326* | ||
| NTRK2 L138P | ||
| Germline variant | ||
| BRCA2 V208G | ||
N/A not applicable, CGP comprehensive genomic profiling, SNV single-nucleotide variant, CNV copy number variant, FOLFOX oxaliplatin, folinic acid and 5-fluorouracil, FOLFIRI irinotecan, folinic acid and 5-fluorouracil, BRAF V-Raf murine sarcoma viral oncogene homolog B1, ATM ataxia telangiectasia mutated, NF1 neurofibromatosis type I, TP53 tumor protein p53, APC adenomatous polyposis coli, ARAF V-Raf murine sarcoma 3611 viral oncogene homolog 1, NTRK2 neurotrophic tyrosine receptor kinase 2, BRCA2 breast cancer susceptibility gene 2, PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide, ERBB2 human epidermal growth factor receptor 2, CCND1 cyclin D1